Ranked #7,502 of 8,699 institutional investors
GordonMD Global Investments LP
Beverely Hills, CA
$129M
US stock portfolio at live prices · today +$1.1M (+0.84%)
Live prices, last trade 12:09 PM ET
- Value at quarter end (Q3 2026)
- $161M
- Change from Q2 2026
- −$25.6M (−13.68%)
- Positions
- 13 · 2 new, 3 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$15.0M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPYXS 22.4%KYTX 15.0%BLCO 7.26%TNGX 6.19%CLDX 5.97%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PYXS Pyxis Oncology, Inc. | 15,541,909 | $28.8M | 22.4% | Added +55% |
| KYTX Kyverna Therapeutics, Inc. | 4,521,318 | $19.4M | 15.0% | Added +7% |
| BLCO Bausch + Lomb Corporation | 475,472 | $9.4M | 7.26% | Reduced −17% |
| TNGX Tango Therapeutics, Inc. | 361,589 | $8.0M | 6.19% | New |
| CLDX Celldex Therapeutics, Inc. | 279,720 | $7.7M | 5.97% | Unchanged |
| VIR Vir Biotechnology, Inc. | 803,552 | $6.9M | 5.38% | Reduced −41% |
| AMGN Amgen Inc. | 14,512 | $6.4M | 4.95% | Reduced −28% |
| ADRX ADARx Pharmaceuticals, Inc. | 450,000 | $6.2M | 4.80% | New |
| INCY Incyte Corporation | 51,080 | $5.9M | 4.58% | Added +18% |
| SRRK Scholar Rock Holding Corporation | 110,500 | $5.6M | 4.34% | Reduced −17% |
| EDIT Editas Medicine, Inc. | 3,127,000 | $5.4M | 4.16% | Unchanged |
| ALLO Allogene Therapeutics, Inc. | 5,298,000 | $3.4M | 2.64% | Unchanged |
| TSHA Taysha Gene Therapies, Inc. | 248,000 | $928K | 0.72% | Reduced −66% |